Zobrazeno 1 - 10
of 747
pro vyhledávání: '"GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS"'
Autor:
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine
Publikováno v:
Journal of Cancer Research and Practice, Vol 11, Iss 2, Pp 57-61 (2024)
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (P
Externí odkaz:
https://doaj.org/article/d84971adb08f42978f5f06cfebdd3568
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The incidence of gastroenteropancreatic neuroendocrine tumors has been rising and these tumors are usually only diagnosed at a metastatic stage. Present first line treatments include somatostatin analogs, targeted therapies and peptide receptor radio
Externí odkaz:
https://doaj.org/article/9c82b79676c344968a050e57dda199bd
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundPatients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a poor prognosis for distant metastasis. Currently, there are no studies on predictive models for the risk of distant metastasis in GEP-NETs.MethodsIn this study, ri
Externí odkaz:
https://doaj.org/article/1da031bbe2394f92a3e3f8ff182896be
Autor:
P. Vladova
Publikováno v:
Trakia Journal of Sciences, Vol 20, Iss 4, Pp 346-353 (2022)
Purpose: Gastroenteropancreatic neuroendocrine tumors are heterogeneous group of tumors. The pathomorphological assessment is essential for the staging and requires an immunohistochemical panel of several markers for validation.The aim of the artic
Externí odkaz:
https://doaj.org/article/0fd276c6c32541d8afa974ae797b4e2a
Autor:
Mark J C van Treijen, Catharina M Korse, Wieke H Verbeek, Margot E T Tesselaar, Gerlof D Valk
Publikováno v:
Endocrine Connections, Vol 11, Iss 10, Pp 1-12 (2022)
Objective: Up to now, serial NETest measurements in individuals assessing the disease course of gastroenteropancreatic neuroendocrine tumors (GEPNETs) at long-term follow-up and treatment response were not studied. Design: The study was a longitudina
Externí odkaz:
https://doaj.org/article/0a52c0ea1c9a45a8b31c3f40d1ebdd11
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kiwoon Baeg, Cynthia Harris, Monica S. Naparst, Eugene Ahn, Sahityasri Thapi, Jacob Martin, Sheila Rustgi, Grace Mhango, Juan Wisnivesky, Michelle Kang Kim
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Medical centers with varying levels of expertise treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are relatively rare tumors. This study assesses the impact of center volume on GEP-NET treatment outcomes. Metho
Externí odkaz:
https://doaj.org/article/5f5cf7af3c844387a7a83ad1aa631fa1
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundRegional lymph node metastasis (LNM) is crucial for planning additional lymphadenectomy, and is directly correlated with poor prognosis in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the patterns of LNM for small (≤2
Externí odkaz:
https://doaj.org/article/9bc4a290b3194da09a4adb107416335c
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs w
Externí odkaz:
https://doaj.org/article/1ad28909df14407db6a0792b29b9c939